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It is still unclear whether the timing of intracoronary stem cell therapy affects the therapeutic response in patients with myo-
cardial infarction. The natural course of healing the infarction and the presence of putative homing signals within the damaged 
myocardium appear to favor cell engraftment during the transendothelial passage in the early days after reperfusion. However, 
the adverse inflammatory environment, with its high oxidative stress, might be deleterious if cells are administered too early 
after reperfusion. Here we highlight several aspects of the timing of intracoronary stem cell therapy. Our results showed that 
transplantation of bone marrow mesenchymal stem cells at 24 weeks after myocardial infarction is more favorable for reduc-
tion of the scar area, inhibition of left ventricular remodeling, and recovery of heart function. Coronary injection of autologous 
bone marrow mesenchymal stem cells at 24 weeks after acute myocardial infarction is safe and does not increase the inci-
dence of complications. 
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Coronary interventional techniques and coronary artery by-
pass surgery are important solutions for myocardial revas-
cularization in patients with coronary artery disease, and 
can significantly enhance the blood supply to the myocar-
dium. However, they cannot significantly improve myocar-
dial remodeling and heart failure in patients by increasing 
the number of working cardiomyocytes in the necrotic re-
gion. In recent years, with the development of molecular 
biology and cell biotechnology techniques, cell therapy has 
caught the attention of researchers around the world. After 
transplantation, cells can survive, proliferate, and replace 
the necrotic myocardium, thereby improving heart function. 
In 2001, Strauer et al. [1] first reported the clinical applica-
tion of stem cell transplantation for improving the heart 
function of patients with myocardial infarction (MI). Thus, 
promising clinical outcomes using stem cell transplantation 
for treatment of ischemic heart diseases have been reported 
by numerous medical research centers. 
However, a number of problems remain to be resolved, 
such as determining the subtype and quantity of the trans-
planted cells, and the timing of transplantation. Strauer et al. 
[2] believed that mononuclear cells in the bone marrow 
consist of many cell types, and that their function is better 
than the solo application of a certain subgroup. However, 
mononuclear cells in the bone marrow contain a smaller 
number of effector cells, which may influence the effects 
after transplantation. In 2002, Toma et al. [3] found that 
amplified adult mesenchymal stem cells transplanted into 
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cardiac muscle were able to differentiate into cardiomyo-
cytes. This finding provided a feasible basis for the applica-
tion of mesenchymal stem cells in cell therapy. Through a 
comparative study of different numbers of transplanted cells, 
Tambara et al. [4] found that the effects of replacing the 
infarcted myocardium and revascularization using 5×107 
cells were better than those using 5×106 and 5×105 cells. 
Besides the subtypes and quantities of the transplanted 
cells, the timing of transplantation is another important fac-
tor that may influence the effects of the treatment. The pre-
sent study aimed to find out the optimal time point after the 
occurrence of acute MI for cell transplantation to provide 
patients with the maximum benefit. To address this issue, 
preclinical and clinical research studies were conducted.  
1  Materials and methods 
1.1  Animal model preparation  
All surgical procedures were performed using Taihu Mei- 
shan pigs (three months of age; 24.5±2.9 kg) provided by 
the Animal Laboratory Center in Soochow University. Ex-
perimental MI was induced by a gelatin sponge embolus 
pushed to the second diagonal branch of the left anterior 
descending coronary artery as previously described [5].  
Bone marrow mesenchymal stem cells (BMSCs) were 
injected into the coronary artery of the pigs at various time 
points after MI. The pigs were randomly divided into five 
groups (n=5): (i) at three hours after MI; (ii) at one day after 
MI; (iii) at three days after MI; (iv) at two weeks after MI; 
and (v) at four weeks after MI. Control groups were treated 
with Dulbecco’s modified Eagle’s medium (DMEM) in-
stead of BMSCs.  
In addition, pigs were treated with pyrrolidine dithiocar-
bamate (PDTC) combined with BMSCs after MI. The pigs 
were randomly divided into four groups (n=5): PDTC+ 
BMSC group: PDTC (100 mg kg1) was intravenously in-
jected at one hour after MI, and BMSCs (1×107/5 mL) were 
injected into the coronary artery at one day after MI; BMSC 
group: physiological saline was intravenously injected at 
one hour after MI, and BMSCs (1×107/5 mL) were injected 
into the coronary artery at one day after MI; PDTC group: 
PDTC (100 mg kg1) was intravenously injected at one hour 
after MI, and 5 mL of physiological saline was injected into 
the coronary artery at one day after MI; control group: 
physiological saline was intravenously injected at one hour 
after MI, and 5 mL of physiological saline was injected into 
the coronary artery at one day after MI. 
1.2  Cell culture and transplantation 
BMSCs were isolated from swine bones and expanded as 
previously described [6]. The BMSCs were transplanted 
into MI models. Five milliliters of the stem cell suspension 
(5 mL of DMEM in the DMEM groups) was injected into 
the left coronary artery using a catheter. 
1.3  Evaluation of cardiac function  
Stroke volume (SV) and end-diastolic wall thickness 
(EDWT) were analyzed by cardiac MRI. Left ventricular 
end-diastolic diameter (LVEDd), left ventricular end-  
systolic diameter (LVEDs), and ejection fraction (EF) were 
analyzed by cardiac ultrasonography in each group prior to 
MI, prior to cell transplantation, and after cell transplanta-
tion. A chart blood pressure module was used to analyze the 
pressure curve and perform the following calculations: left 
ventricular developed pressure (LVDP)=left ventricular 
systolic peak pressure (LVSP)–left ventricular end-diastolic 
pressure (LVEDP); left ventricular maximum shrinkage rate 
change value (+dp/dtmax); and left ventricular maximum 
relaxation rate of change value (−dp/dtmax). 
Myocardial perfusion was assessed by MRI, which 
clearly showed the range of acute MI and the maximum 
level of old MI, and was used to measure the thinning edge 
length and left ventricular perimeter. The infarction size 
was calculated by the percentage of the fibrosis length to the 
perimeter of the left ventricle. 
1.4  Enzyme-linked immunosorbent assay (ELISA)  
Venous blood samples were collected at different times. 
Serum interleukin (IL)-10, tumor necrosis factor (TNF)-α, 
C-reactive protein (CRP) were analyzed using ELISA kits 
(R&D systems, USA).  
1.5  Clinical trials: selected cases and cell transplanta-
tion 
Clinical research was undertaken in the previous two years, 
and was approved by the State Food and Drug Administra-
tion. Proliferated and purified autogenous BMSCs were 
used to provide cell therapy to 42 patients with acute MI. 
The average age of the patients was 64±7.6 years. Cell 
transplantation was undertaken in these patients at the late 
stage of MI (four weeks). Coronary artery injection was 
adopted, with a dosage of 1×107 cells. Eight patients were 
chosen to undergo second cell transplantation at one month 
after the first transplantation, to observe the effects of mul-
tiple transplantations. 
1.6  Clinical trials: evaluation of cardiac function 
The safety of the cell transplantation was evaluated by he-
matological traits, kidney and liver functions, myocardial 
enzymes, electrocardiograms, and 24-h Holter examinations 
at one week, two weeks, and one month after transplantation. 
The effectiveness was evaluated by ultrasonography, serum 
brain natriuretic peptide (BNP) measured using ELISA kit 
(Sangon, China), and other methods. Recent endpoint as-
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sessment and clinical follow-up were undertaken at one 
month and one year after transplantation, respec- tively. 
1.7  Statistical analysis 
All data are expressed as the mean±SD. A t-test was used 
for statistical analyses (=0.05). Values of P<0.05 were 
considered statistically significant. 
2  Results 
2.1  Time window research on stem cell therapy for MI 
2.1.1  Cardiac functional parameters detected by echocar-
diography results 
Following MI, LVEDd and LVEDs were significantly in-
creased, and EF was significantly decreased in each group. 
The control group and the acute phase (three-hour, one-day, 
three-day) groups showed no significant differences after 
transplantation (P>0.05). LVEDd and LVEDs in the 
two-week and four-week groups were significantly reduced. 
EF was significantly increased in the two-week and 
four-week groups after transplantation, and the values in the 
four-week group were greater than those in the two-week 
group (Table 1).  
2.1.2  Left ventricular wall function and infarction size 
detected by cardiac MRI before and after MI 
The ventricular beat and myocardial perfusion were normal 
prior to MI. At four weeks after MI, left ventricular MRI 
indicated a thinned infarct wall, shortened T2 relaxation 
time, reduced myocardial signal, and weakened ventricular 
beat in the thinned segment. Dilatation was also obvious in  
the left ventricular chamber.  
The wall thickness showed no significant differences 
between the acute phase (three-hour, one-day, three-day) 
groups and the control group. The two-week and four-week 
transplantation groups showed obviously thickened end 
walls compared with the acute phase groups and the control 
group, with a greater significant difference in the four-week 
group. The SV of the acute groups and control group was 
decreased compared with the data before transplantation 
(not shown here). The SV of the two-week and four-week 
groups was significantly increased compared with that of 
the control group and the acute phase groups (Table 2). 
2.2  PDTC treatment of acute MI  
2.2.1  IL-10 levels before and after transplantation 
There were no significant differences in the serum IL-10 
levels before MI in all groups (P>0.05). The serum IL-10 
level in the control group reached its highest point on day 7, 
and decreased to the normal level by day 14, with no sig-
nificant difference compared with the data before MI 
(P>0.05). The IL-10 levels in the PDTC group and com-
bined group were higher than those in the control group 
(P<0.05) (Table 3). 
2.2.2  TNF-α levels before and after transplantation 
The serum TNF-α levels before MI showed no significant 
differences in all groups (P>0.05). The serum TNF-α level 
in the control group reached its highest point on day 3, and 
decreased to the normal level by day 14, with no significant 
difference compared with the data before MI (P>0.05). The 
serum TNF-α levels in the PDTC group and combined 
group were lower than those in the control group at 1, 3, and 
7 days after transplantation (P<0.05) (Table 4). 
Table 1  Echocardiography at four weeks after BMSC transplantationa) 
Time of cell 
transplantation 
3 h after MI 1 d after MI 3 d after MI 2 weeks after MI 4 weeks after MI 
DMEM MSCs DMEM MSCs DMEM MSCs DMEM MSCs DMEM MSCs 
LVEDs (mm) 47.74±3.52 46.64±3.32 45.88±5.48 46.21±4.12 44.73±3.69 45.62±4.42 43.50±1.98 36.76±3.02 46.18±3.21 30.82±2.42* 
LVEDd (mm) 56.90±2.26 56.62±2.97※ 55.79±3.56 57.13±4.67※ 54.17±2.86 55.63±3.97※ 55.30±3.40 50.58±2.68 55.10±2.37 45.36±2.48** 
EF (%) 33.3±3.0 35.5±4.2※※ 35.3±3.6 36.2±4.2※※ 34.6±3.4 35.1±4.5※※ 35.3±3.3 43.8±3.1 35.9±2.3 52.8±3.2＃ 
a) *, compared with the 2-week group, P<0.05. **, compared with the 2-week group, P<0.05. ※, compared with the 2-week and 4-week groups, P<0.05; 
compared with the DMEM group, P>0.05. ※※, compared with the 2-week and 4-week groups, P<0.05; compared with the DMEM group, P>0.05. #, 
compared with the 2-week group, P<0.05. 
Table 2  MRI at eight weeks after BMSCs transplantationa) 
Time of cell 
transplantation 
3 h after MI 1 d after MI 3 d after MI 2 weeks after MI 4 weeks after MI 
DMEM MSCs DMEM MSCs DMEM MSCs DMEM MSCs DMEM MSCs 
EDWT (mm) 6.55±0.61 6.88±0.76* 6.85±0.88 6.78±0.72* 6.64±0.53 6.45±0.65* 6.93±0.54 7.51±0.81 6.95±0.69 8.44±0.55** 
SV (mL/beat) 33.51±2.96 34.5±2.31※ 34.96±3.16 34.85±3.33※ 32.89±2.15 32.88±2.79※ 33.28±2.51 37.89±2.86 33.71±2.45 41.64±2.47※※ 
Infarct area (%) 40.60±3.44 42.80±4.66 41.58±3.74 42.48±4.87 41.63±3.24 40.80±3.16 42.20±3.83 34.60±2.07 43.60±3.64 29.80±1.30# 
a) *, compared with the 2-week and 4-week groups, P<0.05. **, compared with the 2-week group, P<0.05. ※, compared with the 2-week and 4-week 
groups, P<0.05; compared with the DMEM group, P>0.05. ※※, compared with the 2-week group, P<0.05; compared with the DMEM group, P<0.05. #, 
compared with the 2-week group, P<0.05. 
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2.2.3 CRP levels before and after transplantation 
The serum CRP levels before MI showed no significant 
differences in all groups (P>0.05). The serum CRP level in 
the control group reached its highest point at three days af-
ter transplantation and decreased to the normal level by 14 
days (P>0.05). The serum CRP levels in the other groups 
showed similar patterns to the control group. The PDTC 
group and combined group had lower levels of IL-10 at 1, 3, 
and 7 days compared with the control group (P<0.05) (Ta-
ble 5). 
2.2.4  Echocardiography 
There were no significant differences in LVDP, +dp/dtmax, 
and −dp/dtmax before MI in all groups (P>0.05). All three 
indexes decreased after MI (P<0.01). LVDP, +dp/dtmax, 
and −dp/dtmax in the combined group were increased at 
four weeks after transplantation compared with those of the 
control group (P<0.05) (Tables 6–8). 
2.3  Clinical translation of cell transplantation 
The serum BNP level was significantly decreased at one 
month after transplantation (478.15±232.07 pg mL1 vs. 
195.45±130.18 pg mL1, P<0.001). The EF was signifi-
cantly increased at one month after transplantation 
(41.3%±12.3% vs. 49.7%±13.9%, P<0.05), but decreased to 
the normal level at six months after transplantation 
(41.3%±12.3% vs. 43.1%±12.4%, P>0.05) (Table 9). These 
findings indicated transient effects of cell transplantation. 
Eight additional cases were chosen to undergo cell trans- 
Table 3  Serum IL-10 levels before and after BMSCs transplantation (pg mL1)a) 
Groups Before infarction After infarction 1 d after transplantation 3 d after transplantation 7 d after transplantation 14 d after transplantation 
Control 17.772±1.86 22.454±2.12* 25.776±2.43* 51.812±1.59* 84.422±2.06* 18.002±1.77 
PDTC 17.9±1.34 26.14±2.05*# 49.826±1.32*# 70.208±1.38*# 85.164±1.35* 17.478±1.33 
Stem cell 17.894±1.84 22.45±2.05* 25.158±2.26* 51.48±1.46* 84.252±2.61* 18.144±0.96 
Mixture 17.46±1.31 26.39±2.28*# 50.358±1.51*# 70.652±1.12*# 85.738±2.79* 18.948±1.06 
a) *, compared with the data before MI, P<0.05. #, compared with the control group, P<0.05. 
Table 4  Serum TNF-α levels before and after BMSCs transplantation (pg mL1)a) 
Groups Before infarction After infarction 1 d after transplantation 3 d after transplantation 7 d after transplantation 14 d after transplantation 
Control 4.912±1.39 5.722±1.45 21.98±3.22* 22.6±4.58* 14.84±4.61* 8.18±1.83* 
PDTC 5.08±0.81 5.844±0.84 9.96±0.99# 10.58±1.13# 9.22±1.07# 7.024±1.01 
Stem cell 5.182±1.36 5.28±1.18 23.8±2.68* 24.62±2.45* 13.244±2.74* 6.94±0.83 
Combined 6.604±1.53 6.956±1.5 11.3±1.41# 12.06±1.42# 9.58±1.2# 7.26±0.81 
a) *, compared with the data before MI, P<0.05. #, compared with the control group, P<0.05. 
Table 5  Serum CRP levels before and after BMSCs transplantation (ng mL1)a) 
Groups Prior to infarction After infarction 1d after transplantation 3d after transplantation 7d after transplantation 14d after transplantation 
control 131.85±17.16 162.35±11.15* 1476±97.49* 1739.6±97.25* 1355.4±81.73* 216.1±23.88* 
PDTC 132±12.82 148.75±3.52* 362.5±27.9*# 391.05±22.06*# 322.7±28.62*# 231.4±22.14* 
Stem cell 126.65±5.69 157.2±14.84* 1529±142.96* 1556.6±170.49* 1138.2±117.24* 226.3±14.85* 
combined 127.95±6.54 145.3±9.35* 385.5±25.66*# 374.65±27.27*# 358.85±22.75*# 231.55±22.25* 
a) *, compared with the data before MI, P<0.05. #, compared with the control group, P<0.05. 
Table 6  +dp/dtmax before and after BMSCs transplantation (mmHg s1)a) 
Groups Before MI After MI After transplantation 
Control 6028.294±90.83 2379.176±54.99* 2234±216.47* 
PDTC 6095.08±140.12 2492.136±135.8* 2337.988±181.16* 
Stem cell 6134.636±127.25 2503.012±96.36* 2321.774±225.24* 
Combined 6226.876±200.51 2416.328±177.07* 3547.702±374.42*# 
a) *, compared with the data before MI, P<0.05. #, compared with the control group, P<0.05. 
Table 7  −dp/dtmax before and after BMSCs transplantation (mmHg s1)a) 
Groups Before MI After MI After transplantation 
Control 4869.922±316.23 1662.588±75.85* 1546.08±131* 
PDTC 4761.61±114.51 1702.904±95.7* 1476.154±135.71* 
Stem cell 4859.766±157.17 1714.52±98.46* 1495.206±119.24* 
Combined 4957.97±242.37 1729.016±62.11* 2601.974±155.81*# 
a) *, compared with the data before MI, P<0.05. #, compared with the control group, P<0.05. 
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Table 8  LVDP before and after BMSCs transplantation (mmHg)a) 
Groups Before MI After MI After transplantation 
Control 128.286±2.56 42.714±3.6* 41.328±2.48* 
PDTC 130.376±4.93 43.254±4.08* 42.376±4.05* 
Stem cell 130.324±4.2 40.334±2.75* 43.006±2.09* 
Combined 130.38±4.41 43.228±2.85* 73.868±2.61*# 
a) *, compared with the data before MI, P<0.05. #, compared with the control group, P<0.05. 
Table 9  Serum BNP levels and EF before and after BMSC transplantation 
Groups 
Prior to 
transplantation 
1 week after 
transplantation 
2 weeks after 
transplantation 
3 weeks after 
transplantation 
1 month after 
transplantation 
6 months after 
transplantation 
1 year after 
transplantation 
BNP 
(pg mL1) 478.15±232.07 402.08±209.16 348.81±205.87 312.90±199.39 195.45±130.18 488±224.12 503±201.85 
EF (%) 41.3±12.3 42.8±14.5 45.7±16.8 47.5±11.5 49.7±13.9 43.1±12.4 40.2±13.2 
 
plantation at one month after the first transplantation. The 
EF was further improved (39.3%±11.3% vs. 51.9%±14.3%, 
P<0.05), indicating a better outcome after multiple trans-
plantations. 
3  Discussion 
Animal studies and preclinical research have demonstrated 
that bone marrow stem cell transplantation can improve 
ischemic heart function [2,7]. Owing to the advantages of 
bone marrow stem cells, such as convenient extraction, ad-
equate number of cells, high survival rate after transplanta-
tion, and low immunogenicity, these cells have become one 
of the more commonly used cells in cell transplantation. 
However, at which time point and what kind of trans-
plantation method could benefit the individuals best have 
been the most concerned topic in cell transplantation. In the 
time window research on the therapeutic effects using stem 
cells for MI, we found that the LVESD, LVEDD and 
EDWT were not significantly changed comparing the 
three-hour, one-day and three-day cell transplantation 
groups with the control groups; however, these values were 
significantly improved when the two-week and four-week 
cell transplantation groups were compared with the acute 
transplantation groups and the control groups; and the ab-
solute values of the reduction of fibrosis area were signifi-
cantly higher in the four-week cell transplantation group 
than in the two-week and acute transplantation groups and 
the control groups. The data indicated that transplantation of 
MSCs in the non-acute phase could partially reverse cardiac 
dilation, delay LV remodeling and thus improve heart func-
tion.  
It is reported that the survival and differentiation abilities 
of transplanted cells were severely inhibited due to local 
tissue ischemia, hypoxia, strong oxidative stress and in-
flammatory responses at one day after MI, and that the bio-
logical effect of the transplanted cells was dramatically 
weakened possibly because of the disastrous effect of in-
flammation [8]. Whereas cell transplantation had an im-
proved efficacy at two weeks after MI, which was possibly 
attributed to that the time point of cell transplantation was 
chosen after the fading inflammation but before scar for-
mation [9]. Schenk et al. [10] found that high expression of 
monocyte chemotactic protein-3 can promote homing of 
BMSCs to the heart at one month after MI. Our results also 
showed that the indicators in the four-week transplantation 
group were superior to those in the other groups, which was 
consistent with the above data. 
The myocardial microenvironment plays an important 
role in the localization and differentiation of BMSCs after 
MI. If the myocardial microenvironment after MI is im-
proved by regulating inflammation, the efficacy of cell 
transplantation can be significantly enhanced. Nuclear fac-
tor (NF)-κB is a multigene regulatory factor in eukaryotic 
cells, and is involved in many biological processes, includ-
ing regulation of innate and adaptive immune responses, 
cell growth, and apoptosis [11]. Oxygen free radicals regu-
late the transcription activity of NF-κB [12]. PDTC is a sta-
ble antioxidant compound that inhibits the production of 
TNF-induced oxygen-derived free radicals and NF-κB ac-
tivity [13,14]. In this study, we inhibited NF-κB activation 
and reduced the level of inflammation by injecting PDTC. 
In our study we used TNF-, CRP and IL-10 to reflect 
the inflammation level. TNF- is believed to play roles in 
antitumor activity, immune modulation and inflammation, 
etc. TNF- is expressed in many types of cells but primarily 
in macrophage cells in response to immunological chal-
lenges such as bacteria (lipopolysaccharides), viruses, para-
sites, mitogens and other cytokines. TNF- appears to be 
directly toxic to vascular endothelial cells. Other actions of 
TNF- include stimulating growth of human fibroblasts and 
other cell lines, activating polymorphonuclear neutrophils 
and osteoclasts, and induction of interleukin-1, prostaglan-
din E2 and collagenase production. CRP is a sensitive indi-
cator of tissue injury. Measuring and charting CRP values 
can prove useful in determining disease progress or the ef-
fectiveness of treatments. The anti-inflammatory effect of 
IL-10 was confirmed in many in vitro and in vivo studies. 
IL-10 played a protective role in animal models of ischemia 
reperfusion and burn injury, through reducing the reactions  
of inflammatory factors and thus minimizing mortality. In 
the control group, the concentration of serum TNF- and 
CRP rapidly increased several hours after MI, peaked at one 
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and three days after MI, reached a platequ and then de-
creased, and returned to the normal level at 14 days after MI. 
The stem cell group had a similar tendency with the control 
group. While in the combined group and the PDTC groups, 
the increment of serum TNF- and CRP level apparently 
slowed down, and the peak values were deduced (P<0.05), 
suggesting that the inflammatory level was dramatically 
reduced inside the animals after using PDTC.  
In 2001, Hamano et al. [15] injected autologous bone 
marrow stem cells into the ischemic myocardium during 
coronary artery bypass graft surgery in five patients with 
old MI. They found that long-term improvement in myocar-
dial perfusion occurred in three patients, while no signifi-
cant changes in the other two cases at one-year follow-up. 
Arrhythmia, myocardial calcification, and neonatal tumors 
did not occur in the five patients. Suárez et al. [16] per-
formed therapy with bone marrow mononuclear cells for 19 
patients with chronic MI. At six-month follow-up, they 
found that the clinical symptoms and cardiac function had 
improved to some extent, and that these improvements were 
retained for the subsequent six months. BNP can be used for 
screening and prognosis of heart failure. It is typically in-
creased in patients with left ventricular dysfunction, with or 
without symptoms. The net effect of BNP is a decrease in 
blood volume, which lowers systemic blood pressure and 
afterload, yielding an increase in cardiac output, partly due 
to a higher ejection fraction. In the present study, the serum 
BNP level was significantly decreased and the left ventric-
ular EF was apparently increased at one month after the 
transplantation. Meanwhile no serious complications oc-
curred after the transplantation of BMSCs. These findings 
are consistent with the results of Mukoyama et al. [17]. 
Regarding the long-term effect of cell transplantation, 
our study suggested that the left ventricular EF in patients 
with chronic MI was apparently increased at one month 
after transplantation, but the improvement was not apparent 
at six months, and that the left ventricular EF at 12 months 
showed no apparent difference compared with that before 
the transplantation, which was consistent with the results of 
the BOOST trial [18]. It is suggested that the effects of stem 
cell transplantation are short-term and mono intracoronary 
transplantation of MSCs has no long-term effect on the im-
provement of LV function, whereas multiple transplanta-
tions had better effects than a single transplantation. There-
fore, the long-term therapeutic effects of cell transplantation 
could be maintained by multiple transplantations and the 
underlying mechanism requires further investigation. 
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